{"success":true,"data":{"pressRelease":{"id":"110064","rtpr_id":"nGNX9rmk8d","ticker":"MGRX","exchange":"NASDAQ","all_tickers":["MGRX"],"title":"Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development","author":"Globe Newswire","published_at":"2026-08-05T20:05:03.672Z","article_body":"The MOU supports exploration of a nuclear test reactor site at the Utah San\nRafael Energy Lab and engagement with the U.S. Department of Energy and\nNuclear Regulatory Commission to advance the Morpheus microreactor toward\ndemonstration and deployment\n\nDallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:\nMGRX) (“Mangoceuticals” or the “Company”) today announced that its\nmerger partner’s wholly owned subsidiary, Nuclea Energy USA Inc. (“Nuclea\nUSA”), has signed a memorandum of understanding (the “MOU”) with the\nState of Utah Office of Energy Development (“OED”) to explore the siting\nof a nuclear test reactor at the Utah San Rafael Energy Lab (“USREL”) to\nadvance the deployment of the Morpheus microreactor.\n\nThe MOU marks an important step in advancing research, development and\ncommercial deployment of Nuclea’s micro-modular reactor. The partnership\nestablished in the MOU will allow Nuclea and OED to explore siting a nuclear\ntest reactor at USREL, support engagement with both the U.S. Department of\nEnergy (DOE) and the Nuclear Regulatory Commission (NRC), and evaluate\npathways for future deployment of Nuclea’s technology in Utah. Through this\npartnership, the parties aim to strengthen Utah’s role as a hub for advanced\nnuclear innovation, testing and demonstration.\n\nThrough Utah’s energy leadership and ambition, USREL has become a premier\nhub for advanced nuclear technology testing and development. Nuclea is proud\nto be joining several other industry innovators, including Valar Atomics and\nNatura Resources, leading significant research and development projects at\nUSREL.\n\n“We are excited to be contributing to and benefitting from the nuclear\ninnovation hub that Utah has fostered at USREL. We are confident that this\npartnership will help to prove the inherent advantages of our technology and\naccelerate our deployment schedule,” said Josef Freundorfer, CEO of Nuclea.\n\n“Nuclea is proud to partner with the State of Utah on the next step in our\ntechnology’s development. We are thrilled to be working with USREL given its\nproven track record of demonstrating advanced power generation\ntechnologies,” said Sagar Sanghera, Chairman & Co-Founder of Nuclea.\n\n“Utah is leading the nation in energy innovation, and our partnership with\nNuclea is another step towards an abundant energy future that is reliable,\nsecure and clean,” said Emy Lesofski, Director, Energy Advisor to the\nGovernor and Director of the Utah Office of Energy Development.\n\n“This MOU represents meaningful progress for our merger partner and\nunderscores the strategic value of the business combination we announced last\nweek,” said Jacob Cohen, Chief Executive Officer of Mangoceuticals.\n“Nuclea’s engagement with the Utah Office of Energy Development, and the\nplanned collaboration with the Department of Energy and Nuclear Regulatory\nCommission, positions the Morpheus microreactor for accelerated advancement\ntoward demonstration and commercial deployment. We remain focused on\ncompleting the transaction and unlocking long-term value for our\nshareholders.”\n\nThis agreement reflects Nuclea’s continued progress in building the\npartnerships needed to advance research, testing, and demonstration activities\nfor the Morpheus microreactor, showcasing the innovative capabilities and\ninherent safety features of its compact lead-cooled reactor technology.\n\nOn July 30, 2026, Mangoceuticals announced that it had entered into a\ndefinitive business combination agreement (the “Business Combination\nAgreement”) with Nuclea.\n\nThe proposed transaction is intended to provide Nuclea with a path to a Nasdaq\npublic listing through Mangoceuticals, broadening access to the capital\nmarkets to fund the continued development, licensing, and commercialization of\nthe Morpheus microreactor at a time when demand for consistent baseload\nelectricity is accelerating.\n\nCompletion of the business combination remains subject to customary closing\nconditions, including the receipt of required stockholder and regulatory\napprovals.\n\nAbout the Utah Office of Energy Development\n\nThe Utah Office of Energy Development (“OED”) is Utah’s primary office\nresponsible for energy and mineral development. The office is charged with\ndeveloping and implementing energy policy and resources, creating\nenergy-related educational and workforce development programs and promoting\nenergy efficiency and modern, resilient infrastructure.\nhttps://energy.utah.gov/\n\nAbout the Utah San Rafael Energy Lab\n\nThe Utah San Rafael Energy Lab (“USREL”) is Utah’s leading hub for\nenergy research and innovation. Located in Emery County, UT, the USREL\nsupports Utah’s any-of-the-above energy strategy by hosting a wide range of\ncutting-edge projects. With state-of-the-art facilities, a team of expert\nresearchers and staff and space for future growth, the USREL is advancing\nenergy solutions to some of today’s most pressing challenges.\nhttps://energylab.utah.gov/\n\nAbout Nuclea Energy Inc.\n\nNuclea Energy Inc. (“Nuclea”) is an advanced nuclear technology company\nheadquartered in Mississauga, Ontario, developing the Morpheus microreactor, a\nlead-cooled, graphite-moderated micro-modular reactor designed to be\nfactory-built, transportable and scalable from approximately 3.5 MWe to 50\nMWe. Nuclea is targeting applications across data centers, defense\ninstallations, remote industrial operations and off-grid communities.\n\nFor more information on Nuclea and the Morpheus(™) microreactor please\nvisit: https://www.nuclea.energy.\n\nNuclea media contact: media@nuclea.energy.\n\nUtah OED Public Information Officer contact: hmcshane@utah.gov.\n\nAbout Mangoceuticals, Inc.\n\nMangoceuticals, Inc., through its subsidiary Mango and Peaches Corp., and its\nbrand, MangoRx, is continued to be focused on developing a variety of men’s\nhealth and wellness products and services via a secure telemedicine platform.\nTo date, the Company currently offers pharmaceutical-based products\nspecifically related to the treatments of erectile dysfunction, hair growth,\nhormone replacement therapies, and weight management. Interested consumers can\nuse MangoRx’s telemedicine platform for a smooth experience. Prescription\nrequests will be reviewed by a licensed medical provider and, if approved,\nfulfilled and discreetly shipped through MangoRx’s partner compounding\npharmacy and right to the patient’s doorstep.\n\nTo learn more about MangoRx’s mission and other products, please\nvisit www.MangoRx.com.\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, including with respect to the proposed business combination between\nNuclea and Mangoceuticals (the “Proposed Transaction”). These\nforward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “think,” “strategy,” “future,” “opportunity,”\n“potential,” “plan,” “seeks,” “may,” “should,” “will,”\n“would,” “will be,” “will continue,” “will likely result,” and\nsimilar expressions, but the absence of these words does not mean that a\nstatement is not forward-looking. These forward-looking statements represent\nNuclea’s expectations or beliefs concerning guidance, future events,\nanticipated revenue, future demand and production levels, macroeconomic\ntrends, the development of ongoing projects, costs and expectations, and it is\npossible that the results described in this news release will not be achieved.\n\nThese forward-looking statements are subject to risks, uncertainties and other\nfactors, many of which are outside of Nuclea’s control, which could cause\nactual results to differ materially from the results discussed in the\nforward-looking statements. These factors include, without limitation: our\nability to advance our proposed products from their current pre-conceptual\nstage to regulatory and commercial readiness; the risk that we may be unable\nto realize our anticipated growth strategies, including the achievement of key\nregulatory and technical milestones, commercialization and our expected\ninternal growth; changes in the availability and cost of professional staff\nand materials; changes in consumer preferences and needs, in our future\ncapital needs and/or in competitive conditions; among others. In addition,\nthere is a risk that the Proposed Transaction may not be completed in a timely\nmanner or at all.\n\nAny forward-looking statement speaks only as of the date on which it is made,\nand, except as required by law, Nuclea does not undertake any obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events or otherwise. New factors emerge from time to time,\nand it is not possible for Nuclea to predict all such factors.\n\nImportant Notices and Additional Information\n\nIn connection with the Proposed Transaction, Mangoceuticals intends to file a\nregistration statement on Form S-4 containing a prospectus with the U.S.\nSecurities and Exchange Commission (the “SEC”). INVESTORS AND SECURITY\nHOLDERS ARE ADVISED TO READ THE REGISTRATION STATEMENT/PROSPECTUS WHEN THEY\nBECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE\nPARTIES AND THE PROPOSED TRANSACTION. Investors and security holders may\nobtain a free copy of the prospectus, the proxy statement and other documents\nfiled by Mangoceuticals and Nuclea (in each case when available) with the SEC\nat the SEC’s website at http://www.sec.gov. Free copies of these documents\nand other filings with the SEC may also be obtained by contacting\nMangoceuticals directly at ir@nuclea.energy or Nuclea at ir@nuclea.energy.\n\nParticipants in the Solicitation\n\nMangoceuticals, Nuclea and their respective directors, executive officers and\nother members of management and employees may, under SEC rules, be deemed to\nbe participants in the solicitation of proxies from Mangoceuticals’\nstockholders in connection with the transaction. Investors and security\nholders may obtain more detailed information regarding the names, affiliations\nand interests of Mangoceuticals’ executive officers and directors in its\nmost recent Annual Report on Form 10-K and other filings with the SEC.\nAdditional information regarding the persons who may be deemed participants in\nthe solicitation and their interests will be set forth in the proxy statement\nand other relevant materials when they become available.\n\nNo Offer or Solicitation\n\nThis news release is not a proxy statement or solicitation of a proxy, consent\nor authorization with respect to any securities or in respect of the Proposed\nTransaction contemplated by the Business Combination Agreement and shall not\nconstitute an offer to sell or a solicitation of an offer to buy any\nsecurities, or a solicitation of any vote or approval, nor shall there be any\nsale of securities in any state or jurisdiction in which such offer,\nsolicitation, or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of the Securities Act of 1933, as amended, or an exemption\ntherefrom.\n\nFOR INVESTOR RELATIONS\n\nNuclea Energy Inc.\nCORE IR\nir@nuclea.energy\n(437) 784-1600\n\nMangoceuticals, Inc.\ninvestors@mangorx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/424c2f93-0321-4df2-98b6-6a7970d20bd4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9rmk8d","title":"Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development","author":"Globe Newswire","ticker":"MGRX","created":"2026-08-05T20:05:03.672Z","tickers":["MGRX"],"exchange":"NASDAQ","article_body":"The MOU supports exploration of a nuclear test reactor site at the Utah San\nRafael Energy Lab and engagement with the U.S. Department of Energy and\nNuclear Regulatory Commission to advance the Morpheus microreactor toward\ndemonstration and deployment\n\nDallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:\nMGRX) (“Mangoceuticals” or the “Company”) today announced that its\nmerger partner’s wholly owned subsidiary, Nuclea Energy USA Inc. (“Nuclea\nUSA”), has signed a memorandum of understanding (the “MOU”) with the\nState of Utah Office of Energy Development (“OED”) to explore the siting\nof a nuclear test reactor at the Utah San Rafael Energy Lab (“USREL”) to\nadvance the deployment of the Morpheus microreactor.\n\nThe MOU marks an important step in advancing research, development and\ncommercial deployment of Nuclea’s micro-modular reactor. The partnership\nestablished in the MOU will allow Nuclea and OED to explore siting a nuclear\ntest reactor at USREL, support engagement with both the U.S. Department of\nEnergy (DOE) and the Nuclear Regulatory Commission (NRC), and evaluate\npathways for future deployment of Nuclea’s technology in Utah. Through this\npartnership, the parties aim to strengthen Utah’s role as a hub for advanced\nnuclear innovation, testing and demonstration.\n\nThrough Utah’s energy leadership and ambition, USREL has become a premier\nhub for advanced nuclear technology testing and development. Nuclea is proud\nto be joining several other industry innovators, including Valar Atomics and\nNatura Resources, leading significant research and development projects at\nUSREL.\n\n“We are excited to be contributing to and benefitting from the nuclear\ninnovation hub that Utah has fostered at USREL. We are confident that this\npartnership will help to prove the inherent advantages of our technology and\naccelerate our deployment schedule,” said Josef Freundorfer, CEO of Nuclea.\n\n“Nuclea is proud to partner with the State of Utah on the next step in our\ntechnology’s development. We are thrilled to be working with USREL given its\nproven track record of demonstrating advanced power generation\ntechnologies,” said Sagar Sanghera, Chairman & Co-Founder of Nuclea.\n\n“Utah is leading the nation in energy innovation, and our partnership with\nNuclea is another step towards an abundant energy future that is reliable,\nsecure and clean,” said Emy Lesofski, Director, Energy Advisor to the\nGovernor and Director of the Utah Office of Energy Development.\n\n“This MOU represents meaningful progress for our merger partner and\nunderscores the strategic value of the business combination we announced last\nweek,” said Jacob Cohen, Chief Executive Officer of Mangoceuticals.\n“Nuclea’s engagement with the Utah Office of Energy Development, and the\nplanned collaboration with the Department of Energy and Nuclear Regulatory\nCommission, positions the Morpheus microreactor for accelerated advancement\ntoward demonstration and commercial deployment. We remain focused on\ncompleting the transaction and unlocking long-term value for our\nshareholders.”\n\nThis agreement reflects Nuclea’s continued progress in building the\npartnerships needed to advance research, testing, and demonstration activities\nfor the Morpheus microreactor, showcasing the innovative capabilities and\ninherent safety features of its compact lead-cooled reactor technology.\n\nOn July 30, 2026, Mangoceuticals announced that it had entered into a\ndefinitive business combination agreement (the “Business Combination\nAgreement”) with Nuclea.\n\nThe proposed transaction is intended to provide Nuclea with a path to a Nasdaq\npublic listing through Mangoceuticals, broadening access to the capital\nmarkets to fund the continued development, licensing, and commercialization of\nthe Morpheus microreactor at a time when demand for consistent baseload\nelectricity is accelerating.\n\nCompletion of the business combination remains subject to customary closing\nconditions, including the receipt of required stockholder and regulatory\napprovals.\n\nAbout the Utah Office of Energy Development\n\nThe Utah Office of Energy Development (“OED”) is Utah’s primary office\nresponsible for energy and mineral development. The office is charged with\ndeveloping and implementing energy policy and resources, creating\nenergy-related educational and workforce development programs and promoting\nenergy efficiency and modern, resilient infrastructure.\nhttps://energy.utah.gov/\n\nAbout the Utah San Rafael Energy Lab\n\nThe Utah San Rafael Energy Lab (“USREL”) is Utah’s leading hub for\nenergy research and innovation. Located in Emery County, UT, the USREL\nsupports Utah’s any-of-the-above energy strategy by hosting a wide range of\ncutting-edge projects. With state-of-the-art facilities, a team of expert\nresearchers and staff and space for future growth, the USREL is advancing\nenergy solutions to some of today’s most pressing challenges.\nhttps://energylab.utah.gov/\n\nAbout Nuclea Energy Inc.\n\nNuclea Energy Inc. (“Nuclea”) is an advanced nuclear technology company\nheadquartered in Mississauga, Ontario, developing the Morpheus microreactor, a\nlead-cooled, graphite-moderated micro-modular reactor designed to be\nfactory-built, transportable and scalable from approximately 3.5 MWe to 50\nMWe. Nuclea is targeting applications across data centers, defense\ninstallations, remote industrial operations and off-grid communities.\n\nFor more information on Nuclea and the Morpheus(™) microreactor please\nvisit: https://www.nuclea.energy.\n\nNuclea media contact: media@nuclea.energy.\n\nUtah OED Public Information Officer contact: hmcshane@utah.gov.\n\nAbout Mangoceuticals, Inc.\n\nMangoceuticals, Inc., through its subsidiary Mango and Peaches Corp., and its\nbrand, MangoRx, is continued to be focused on developing a variety of men’s\nhealth and wellness products and services via a secure telemedicine platform.\nTo date, the Company currently offers pharmaceutical-based products\nspecifically related to the treatments of erectile dysfunction, hair growth,\nhormone replacement therapies, and weight management. Interested consumers can\nuse MangoRx’s telemedicine platform for a smooth experience. Prescription\nrequests will be reviewed by a licensed medical provider and, if approved,\nfulfilled and discreetly shipped through MangoRx’s partner compounding\npharmacy and right to the patient’s doorstep.\n\nTo learn more about MangoRx’s mission and other products, please\nvisit www.MangoRx.com.\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, including with respect to the proposed business combination between\nNuclea and Mangoceuticals (the “Proposed Transaction”). These\nforward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “think,” “strategy,” “future,” “opportunity,”\n“potential,” “plan,” “seeks,” “may,” “should,” “will,”\n“would,” “will be,” “will continue,” “will likely result,” and\nsimilar expressions, but the absence of these words does not mean that a\nstatement is not forward-looking. These forward-looking statements represent\nNuclea’s expectations or beliefs concerning guidance, future events,\nanticipated revenue, future demand and production levels, macroeconomic\ntrends, the development of ongoing projects, costs and expectations, and it is\npossible that the results described in this news release will not be achieved.\n\nThese forward-looking statements are subject to risks, uncertainties and other\nfactors, many of which are outside of Nuclea’s control, which could cause\nactual results to differ materially from the results discussed in the\nforward-looking statements. These factors include, without limitation: our\nability to advance our proposed products from their current pre-conceptual\nstage to regulatory and commercial readiness; the risk that we may be unable\nto realize our anticipated growth strategies, including the achievement of key\nregulatory and technical milestones, commercialization and our expected\ninternal growth; changes in the availability and cost of professional staff\nand materials; changes in consumer preferences and needs, in our future\ncapital needs and/or in competitive conditions; among others. In addition,\nthere is a risk that the Proposed Transaction may not be completed in a timely\nmanner or at all.\n\nAny forward-looking statement speaks only as of the date on which it is made,\nand, except as required by law, Nuclea does not undertake any obligation to\nupdate or revise any forward-looking statement, whether as a result of new\ninformation, future events or otherwise. New factors emerge from time to time,\nand it is not possible for Nuclea to predict all such factors.\n\nImportant Notices and Additional Information\n\nIn connection with the Proposed Transaction, Mangoceuticals intends to file a\nregistration statement on Form S-4 containing a prospectus with the U.S.\nSecurities and Exchange Commission (the “SEC”). INVESTORS AND SECURITY\nHOLDERS ARE ADVISED TO READ THE REGISTRATION STATEMENT/PROSPECTUS WHEN THEY\nBECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE\nPARTIES AND THE PROPOSED TRANSACTION. Investors and security holders may\nobtain a free copy of the prospectus, the proxy statement and other documents\nfiled by Mangoceuticals and Nuclea (in each case when available) with the SEC\nat the SEC’s website at http://www.sec.gov. Free copies of these documents\nand other filings with the SEC may also be obtained by contacting\nMangoceuticals directly at ir@nuclea.energy or Nuclea at ir@nuclea.energy.\n\nParticipants in the Solicitation\n\nMangoceuticals, Nuclea and their respective directors, executive officers and\nother members of management and employees may, under SEC rules, be deemed to\nbe participants in the solicitation of proxies from Mangoceuticals’\nstockholders in connection with the transaction. Investors and security\nholders may obtain more detailed information regarding the names, affiliations\nand interests of Mangoceuticals’ executive officers and directors in its\nmost recent Annual Report on Form 10-K and other filings with the SEC.\nAdditional information regarding the persons who may be deemed participants in\nthe solicitation and their interests will be set forth in the proxy statement\nand other relevant materials when they become available.\n\nNo Offer or Solicitation\n\nThis news release is not a proxy statement or solicitation of a proxy, consent\nor authorization with respect to any securities or in respect of the Proposed\nTransaction contemplated by the Business Combination Agreement and shall not\nconstitute an offer to sell or a solicitation of an offer to buy any\nsecurities, or a solicitation of any vote or approval, nor shall there be any\nsale of securities in any state or jurisdiction in which such offer,\nsolicitation, or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction. No offer of\nsecurities shall be made except by means of a prospectus meeting the\nrequirements of the Securities Act of 1933, as amended, or an exemption\ntherefrom.\n\nFOR INVESTOR RELATIONS\n\nNuclea Energy Inc.\nCORE IR\nir@nuclea.energy\n(437) 784-1600\n\nMangoceuticals, Inc.\ninvestors@mangorx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/424c2f93-0321-4df2-98b6-6a7970d20bd4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-05T20:05:05.056995436Z","server_sent_at_ms":1785960305056},"received_at":"2026-08-05T20:05:05.121Z","source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339719/0/en/mangoceuticals-merger-partner-nuclea-energy-nuclea-executes-mou-with-utah-office-of-energy-development.html"},"analysis":{"id":"99067","press_release_id":"110064","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["completion of the business combination remains subject to customary closing conditions","merger partner's technology is in pre-conceptual to early development stage","risk that the proposed transaction may not be completed"],"eventType":"partnership","narrative":"Nuclea Energy, Mangoceuticals' pending merger partner, signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab.\n\nThe agreement aims to advance Nuclea's Morpheus microreactor, a lead-cooled system scalable from 3.5 MWe to 50 MWe, by supporting engagement with the DOE and NRC.\n\nMangoceuticals CEO Jacob Cohen noted the MOU underscores the strategic value of the business combination announced on July 30, which remains subject to shareholder and regulatory approvals.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Merger target secures state-level partnership for reactor testing, supporting the pending business combination."},"keyFigures":{"customDimensions":{"reactor_capacity_max":"50 MWe","reactor_capacity_min":"3.5 MWe"}},"quotedText":"This MOU represents meaningful progress for our merger partner and underscores the strategic value of the business combination we announced last week","namedEntities":{"people":[{"name":"Josef Freundorfer","role":"CEO of Nuclea"},{"name":"Sagar Sanghera","role":"Chairman & Co-Founder of Nuclea"},{"name":"Emy Lesofski","role":"Director, Utah Office of Energy Development"},{"name":"Jacob Cohen","role":"CEO of Mangoceuticals"}],"products":["Morpheus microreactor","MangoRx"],"companies":[{"name":"Nuclea Energy","relationship":"merger partner"},{"name":"Utah Office of Energy Development","relationship":"partner"},{"name":"Utah San Rafael Energy Lab","relationship":"project site"},{"name":"U.S. Department of Energy","relationship":"regulatory body"},{"name":"Nuclear Regulatory Commission","relationship":"regulatory body"},{"name":"Valar Atomics","relationship":"industry peer"},{"name":"Natura Resources","relationship":"industry peer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Non-binding MOU to explore a test reactor site represents progress for the merger target, but does not guarantee revenue, regulatory approval, or completion of the pending business combination."},"tickerRelevance":{"others":[],"primary":"MGRX"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":["m_and_a"],"importanceComponents":{"tickerTier":"small/micro-cap","eventGravity":"non-binding MOU for test site","sectorWeight":"niche nuclear pivot"}},"event_type":"partnership","event_type_secondary":["m_and_a"],"sentiment":"bullish","material_impact_score":2,"narrative":"Nuclea Energy, Mangoceuticals' pending merger partner, signed a memorandum of understanding with the Utah Office of Energy Development to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab.\n\nThe agreement aims to advance Nuclea's Morpheus microreactor, a lead-cooled system scalable from 3.5 MWe to 50 MWe, by supporting engagement with the DOE and NRC.\n\nMangoceuticals CEO Jacob Cohen noted the MOU underscores the strategic value of the business combination announced on July 30, which remains subject to shareholder and regulatory approvals.","key_figures":{"customDimensions":{"reactor_capacity_max":"50 MWe","reactor_capacity_min":"3.5 MWe"}},"named_entities":{"people":[{"name":"Josef Freundorfer","role":"CEO of Nuclea"},{"name":"Sagar Sanghera","role":"Chairman & Co-Founder of Nuclea"},{"name":"Emy Lesofski","role":"Director, Utah Office of Energy Development"},{"name":"Jacob Cohen","role":"CEO of Mangoceuticals"}],"products":["Morpheus microreactor","MangoRx"],"companies":[{"name":"Nuclea Energy","relationship":"merger partner"},{"name":"Utah Office of Energy Development","relationship":"partner"},{"name":"Utah San Rafael Energy Lab","relationship":"project site"},{"name":"U.S. Department of Energy","relationship":"regulatory body"},{"name":"Nuclear Regulatory Commission","relationship":"regulatory body"},{"name":"Valar Atomics","relationship":"industry peer"},{"name":"Natura Resources","relationship":"industry peer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T00:14:32.005Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small/micro-cap","eventGravity":"non-binding MOU for test site","sectorWeight":"niche nuclear pivot"}},"durationMs":107261,"modelName":"glm-4.7"}}